Skip to main content
Top
Published in: Clinical Rheumatology 1/2016

01-01-2016 | Case Based Review

Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature

Authors: Sara Monti, Nicola Boffini, Marco Lucioni, Marco Paulli, Carlomaurizio Montecucco, Roberto Caporali

Published in: Clinical Rheumatology | Issue 1/2016

Login to get access

Abstract

We report the case of a 52-year-old man with long-standing HLAB27-positive ankylosing spondylitis treated with anti-tumour necrosis factor (TNF) alpha therapy who was admitted to our rheumatology department complaining of increasing lumbar and buttock pain radiating to the posterior thigh, associated with numbness in the leg, gait disturbance and low-grade fever. The clinical picture was initially interpreted as a flare of disease but was not responsive to treatment. A contrast-enhanced spinal MRI was performed with evidence of a diffuse signal abnormality involving the sacroiliac joints and the spine, with evidence of spondylodiscitis of L5 and with a lesion causing L5-S1 root compression and infiltrating the iliopsoas muscle. These findings confirmed the possibility of a reactivation of disease associated with an infectious process. The most frequent causes of infectious spondylodiscitis were excluded, and a biopsy was then performed. Histological analysis revealed a high-grade B-cell non-Hodgkin’s lymphoma of the spine. This case highlights how a differential diagnosis of low back pain with neurological symptoms can be particularly troublesome in ankylosing spondylitis and that continuous vigilance is warranted in patients treated with long-term immunosuppressive therapies.
Literature
2.
go back to reference Hochberg MC, Silman AJ, Smolen JS et al (2011) Rheumatology. Mosby Elsevier, Philadelphia Hochberg MC, Silman AJ, Smolen JS et al (2011) Rheumatology. Mosby Elsevier, Philadelphia
3.
go back to reference Pallavicini FB, Caporali R, Sarzi-Puttini P et al (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180PubMedCrossRef Pallavicini FB, Caporali R, Sarzi-Puttini P et al (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180PubMedCrossRef
4.
go back to reference Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRef
5.
go back to reference Askling J, Klareskog L, Blomqvist P et al (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65:1184–1187PubMedPubMedCentralCrossRef Askling J, Klareskog L, Blomqvist P et al (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65:1184–1187PubMedPubMedCentralCrossRef
6.
go back to reference Mariette X, Tubach F, Bagheri H et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedPubMedCentralCrossRef Mariette X, Tubach F, Bagheri H et al (2010) Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 69:400–408PubMedPubMedCentralCrossRef
8.
go back to reference Nannini C, Cantini F, Niccoli L et al (2009) Single-centre series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61:801–812PubMedCrossRef Nannini C, Cantini F, Niccoli L et al (2009) Single-centre series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61:801–812PubMedCrossRef
9.
go back to reference the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, Van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591CrossRef the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, Van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591CrossRef
10.
go back to reference Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet 359:1187–1193PubMedCrossRef Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet 359:1187–1193PubMedCrossRef
11.
go back to reference Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543–1551PubMedCrossRef Braun J, van der Horst-Bruinsma IE, Huang F et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63:1543–1551PubMedCrossRef
12.
go back to reference Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274–280PubMedCrossRef Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274–280PubMedCrossRef
13.
go back to reference Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–1145PubMedCrossRef Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–1145PubMedCrossRef
14.
go back to reference Burmester GR, Panaccione R, Gordon KB et al (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72:517–524PubMedPubMedCentralCrossRef Burmester GR, Panaccione R, Gordon KB et al (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72:517–524PubMedPubMedCentralCrossRef
15.
go back to reference Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedPubMedCentralCrossRef Geborek P, Bladström A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedPubMedCentralCrossRef
16.
go back to reference Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef
17.
go back to reference Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef
18.
go back to reference Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751PubMedCrossRef Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751PubMedCrossRef
19.
go back to reference Greenberg J, Strand V, Keystone E, at al (2007) TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282) American College of Rheumatology Annual Meeting Greenberg J, Strand V, Keystone E, at al (2007) TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years (Abstract 282) American College of Rheumatology Annual Meeting
20.
go back to reference Askling J, Baecklund E, Granath F et al (2009) Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:648–653PubMedCrossRef Askling J, Baecklund E, Granath F et al (2009) Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:648–653PubMedCrossRef
21.
go back to reference Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290–295PubMed Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290–295PubMed
22.
go back to reference Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690–1699CrossRef Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology (Oxford) 50:1690–1699CrossRef
23.
go back to reference Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J (2013) Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 15:R67PubMedPubMedCentralCrossRef Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J (2013) Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 15:R67PubMedPubMedCentralCrossRef
24.
go back to reference Carmona L, Gómez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72PubMedPubMedCentralCrossRef Carmona L, Gómez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72PubMedPubMedCentralCrossRef
25.
go back to reference Jantunen E, Myllykangas-Luosujärvi R, Kaipiainen-Seppänen O (2000) Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 39:563–564CrossRef Jantunen E, Myllykangas-Luosujärvi R, Kaipiainen-Seppänen O (2000) Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford) 39:563–564CrossRef
26.
go back to reference Khan SY, Hutchinson DG (2004) Primary synovial non-Hodgkin’s lymphoma in association with ankylosing spondylitis. Rheumatology (Oxford) 43:391CrossRef Khan SY, Hutchinson DG (2004) Primary synovial non-Hodgkin’s lymphoma in association with ankylosing spondylitis. Rheumatology (Oxford) 43:391CrossRef
27.
go back to reference Kim YS, Kim HS (2012) Ankylosing spondylitis accompanying with Hodgkin’s lymphoma. Int J Rheum Dis 15:e68–e70PubMedCrossRef Kim YS, Kim HS (2012) Ankylosing spondylitis accompanying with Hodgkin’s lymphoma. Int J Rheum Dis 15:e68–e70PubMedCrossRef
28.
go back to reference Aksu K, Cagirgan S, Ozsan N et al (2011) Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 31:1645–1647PubMedCrossRef Aksu K, Cagirgan S, Ozsan N et al (2011) Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 31:1645–1647PubMedCrossRef
29.
go back to reference Aksu K, Donmez A, Ertan Y et al (2007) Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 28:185–187PubMedCrossRef Aksu K, Donmez A, Ertan Y et al (2007) Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int 28:185–187PubMedCrossRef
30.
go back to reference Jung KH, Lim MJ, Kwon SR et al (2013) Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept. Mod Rheumatol 23:817–822PubMedCrossRef Jung KH, Lim MJ, Kwon SR et al (2013) Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept. Mod Rheumatol 23:817–822PubMedCrossRef
31.
go back to reference Mally R, Sharma M, Khan S et al (2011) Primary lumbo-sacral spinal epidural non-Hodgkin’s lymphoma: a case report and review of literature. Asian Spine J 5:192–195PubMedPubMedCentralCrossRef Mally R, Sharma M, Khan S et al (2011) Primary lumbo-sacral spinal epidural non-Hodgkin’s lymphoma: a case report and review of literature. Asian Spine J 5:192–195PubMedPubMedCentralCrossRef
33.
go back to reference Toussirot E, Chataigner H, Pépin L et al (2009) Spinal cord compression complicating aseptic spondylodiscitis in ankylosing spondylitis. Clin Exp Rheumatol 27:654–657PubMed Toussirot E, Chataigner H, Pépin L et al (2009) Spinal cord compression complicating aseptic spondylodiscitis in ankylosing spondylitis. Clin Exp Rheumatol 27:654–657PubMed
34.
go back to reference BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131PubMedCentralCrossRef BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131PubMedCentralCrossRef
35.
go back to reference Xie X, Li F, Chen JW, Wang J (2013) Risk of tuberculosis infection in atni-TNFα biological therapy: from bench to bedside. J Microbiol Immunol Infect 30:S1684–1182 Xie X, Li F, Chen JW, Wang J (2013) Risk of tuberculosis infection in atni-TNFα biological therapy: from bench to bedside. J Microbiol Immunol Infect 30:S1684–1182
36.
go back to reference McCain GA, Harth M, Bell DA et al (1981) Septic Discitis. J Rheumatol 8:100–109PubMed McCain GA, Harth M, Bell DA et al (1981) Septic Discitis. J Rheumatol 8:100–109PubMed
37.
go back to reference Fantoni M, Trecarichi EM, Rossi B et al (2012) Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 2:2–7 Fantoni M, Trecarichi EM, Rossi B et al (2012) Epidemiological and clinical features of pyogenic spondylodiscitis. Eur Rev Med Pharmacol Sci 2:2–7
Metadata
Title
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature
Authors
Sara Monti
Nicola Boffini
Marco Lucioni
Marco Paulli
Carlomaurizio Montecucco
Roberto Caporali
Publication date
01-01-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2594-2

Other articles of this Issue 1/2016

Clinical Rheumatology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.